KR20190029996A - Release controlled oral dosage form comprising itopride - Google Patents

Abstract

An oral administration type sustained-release bilayer tablet containing itopride hydrochloride or a salt thereof of the present invention is a sustained-release bilayer tablet, comprised with an immediate-release layer which allows drugs to be rapidly eluted and a sustained-release layer which allows drugs to be slowly eluted, in order to simultaneously satisfy both the rapid expression of pharmacological activity and the 24-hour duration of the pharmacological activity. In order to exhibit an optimal aspect of elution, the oral administration type sustained-release bilayer tablet mixed three types of hydroxypropyl methylcellulose with different viscosities and used the same as a release-controlling agent, and controls the dissolution rate and a residence time in gastrointestinal tracts with different pHs. In addition, the present invention provides a method for manufacturing the oral administration type sustained-release bilayer tablet containing itopride hydrochloride which increases drug compliance of a patient and exhibits excellent effects as described above.

Description

TECHNICAL FIELD [0001] The present invention relates to an oral preparation for oral administration containing itopride hydrochloride,

The present invention relates to once-daily oral sustained-release double-layered tablets containing itopride which has been precisely adjusted in its elution pattern using three kinds of hydroxypropylmethylcellulose whose dissolution characteristics differ according to the viscosity, and a preparation method thereof.

Itopride hydrochloride (N - [[4- (2-dimethylaminoethoxy) phenyl] methyl] -3,4-dimethoxybenzamide) has abdominal bloating due to functional dyspepsia, abdominal pain, anorexia, chest pain, , Vomiting, and the like, and has the following chemical formula.

Itopride hydrochloride blocks the dopamine D2 receptor and inhibits acetylcholinesterase, thereby increasing the concentration of acetylcholine in the body. Increased acetylcholine further enhances gastrointestinal motility, increases the pressure of the lower esophageal sphincter, accelerates gastric emptying, improves gastric and duodenal coordination, improves digestive function deterioration, and relieves abdominal pain .

In addition, itopride hydrochloride has advantages such as long-term use because it does not show side effects such as gynecomastia and lactic acid secretion, which are side effects of gastrointestinal function-improving agents such as domperidone.

Itopride hydrochloride is usually administered orally within 30 minutes, and the time to reach the peak plasma concentration is about 0.5 to 1.5 hours and the duration is about 12 hours. About 80% of the active ingredient is known to be excreted in the urine, and the excretion rate (half-life) is known to be about 6 hours.

In general, patients suffering from poor digestive function frequently develop symptoms due to stress and are required to take a long term. As described above, itopride hydrochloride should be taken regularly three times a day due to its short half-life . This leads to inconvenience in the guidance of medication for long - term patients, and also in compliance with medication.

In order to solve such a problem, Korean Patent No. 10-1485421 discloses a slow release tablet containing itopride once a day, but the slow release tablet is obtained by applying a release delay matrix to a single tablet containing itopride hydrochloride, And there is a disadvantage in that the efficacy is deteriorated because the elution is gradually made after administration.

The present invention provides a sustained-release bi-layer tablet comprising a herbicidal layer and a sustained-release layer containing itopride hydrochloride, and the sustained-release bi-layer tablet according to the present invention achieves sufficient pharmacological activity only once per day, And exhibits excellent effects.

Korean Patent No. 10-1485421

DISCLOSURE Technical Problem Accordingly, the present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to further improve the sustained-release schedule technology, thereby satisfying the simultaneous expression of rapid pharmacological activity and sustained pharmacological activity for 24 hours, To provide a sustained release double-layered tablets containing itopride hydrochloride which exhibits excellent pharmacological activity, and a process for producing the same.

The present invention provides once-daily orally-administered sustained-release or controlled-release double-layer tablets containing itopride hydrochloride as an active ingredient.

Wherein the sustained release or controlled release two-ply tablets comprise a sustained layer comprising an active ingredient, a filler, a binder, a disintegrant, and a sustained release layer comprising an active ingredient, a filler, a binder, a disintegrant and a release modifier, Hydroxypropylmethylcellulose having a viscosity of 75,000 to 140,000 mPa.s, hydroxypropylmethylcellulose having a viscosity of 11,250 to 21,000 mPa.s and hydroxypropylmethylcellulose having a viscosity of 3,000 to 5,600 mPa.s are mixed and used do,

The amount of the hydroxypropylmethylcellulose having a viscosity of 75,000 to 140,000 mPa.s based on the total weight of the release controlling agent is 40 to 55% by weight, the viscosity of the hydroxypropylmethylcellulose having a viscosity of 11,250 to 21,000 mPa.s is 15 to 15% 35% by weight of hydroxypropylmethylcellulose having a viscosity of 3,000 to 5,600 mPa.s, and 25 to 35% by weight of hydroxypropylmethylcellulose.

When the hydroxypropylmethylcellulose having a viscosity of 75,000 to 140,000 mPa.s is less than 40% by weight, sufficient sustained release can not be attained. When it exceeds 55% by weight, sufficient amount of effective drug is not eluted per hour, .

The hydroxypropylmethylcellulose having a viscosity of 11,250 to 21,000 mPa.s serves to uniformly and precisely control the elution amount of the active ingredient for a long period of time. When the content is less than 15% by weight, the elution pattern with time becomes uneven , And when it exceeds 35% by weight, the sustained-release effect decreases.

On the other hand, when the content of hydroxypropylmethylcellulose having a viscosity of 3,000 to 5,600 mPa.s is less than 25% by weight, elution of sufficient effective drug is not achieved in the early stage, and when it exceeds 35% by weight, Fall off.

The sustained-release bi-layered tablet according to the present invention is characterized in that the active ingredient is contained in each of the immediate-release layer and the sustained-release layer, and the content of each effective ingredient is 20 to 60 mg for the immediate-release layer and 90 to 130 mg for the extended- .

If the effective amount of the immediate-release layer is less than 20 mg or the effective amount of the sustained-release layer is less than 90 mg, a sufficient therapeutic effect is not obtained. If the effective amount of the immediate-release layer exceeds 60 mg or the effective amount of the sustained-release layer exceeds 130 mg, the blood concentration may excessively increase and side effects may occur .

The sustained-release layer composition of the sustained-release bi-layer tablet according to the present invention may contain 30 to 45% by weight of itopride hydrochloride, 10 to 20% by weight of release modifier, and 2 to 20% by weight of low-substituted hydroxypropyl cellulose, based on the total weight of the total sustained- To 5% by weight, and 2 to 5% by weight of Povidone K-30.

When the content of the release modifying agent is out of the above range, excessive dissolution occurs in the initial stage of administration or the dissolution is delayed excessively, It is preferred that the low-substituted propyl cellulose as the disintegrant and the povidone K-30 as the binder also affect the dissolution rate, so that they do not deviate from the above range.

The total weight of the sustained-release sustained-release double-layer tablet containing itopride hydrochloride of the present invention is 400 to 500 mg. If the total weight is less than 400 mg, there may be a problem with the stability of the sustained-release preparation, and if it exceeds 500 mg, Can fall.

The itopride hydrochloride-containing orally administrable sustained release bi-layer tablet of the present invention can be prepared in various forms, but the thickness of the formulation is preferably 4 to 9 mm. When the thickness is less than 4 mm, cracks are formed or collapsed in the tablets during tableting, resulting in poor yield. The stability of the finished tablets may be poor and the formulations may be broken even under small impact. When the tablet is over 9 mm, It can be felt difficult depending on the condition such as constitution, age, disease and the like.

Meanwhile, the itopride hydrochloride-containing sustained-release double-layer tablet once orally administered once daily according to the present invention,

Mixing itopride hydrochloride granules, release modifiers, fillers, binders and disintegrants to produce sustained-release granules;

Mixing the itopride hydrochloride granule, the filler, the binder and the disintegrant to produce a granule of the immediate layer;

And compressing the granules of the immediate-release layer and the granules of the sustained-release layer at a force of 3.0 to 8.0 kgf per unit area of 1 cm 2 to prepare a single tablet.

At this time, it is preferable that the grain size of the sustained-release layer is in the range of 350 to 450 탆. When the granular particle size is less than 350 탆, stability is inferior and the dissolution profile of the active ingredient is uneven. When it exceeds 450 탆, The elution of the active ingredient is not sufficiently performed.

Preferably, the force for pressing in the single tablet production step is 3 to 8 kgf / cm 2, more preferably 4 to 6 kgf / cm 2. When the pressure is less than 3 kgf / cm 2, the sustained release matrix structure by the release modifier easily collapses, If the concentration exceeds 8 kgf / cm < 2 >, the elution is excessively delayed, which makes it difficult to maintain the concentration of the active ingredient continuously.

The sustained release double-layered tablets containing itopride hydrochloride according to the present invention preferably have a hardness of 10 to 25 kg / cm 2, more preferably 15 to 20 kg / cm 2.

When the hardness is less than 10 kgf / cm 2, the dissolution of the drug in the early phase may occur due to some disintegration of the slow release layer. It appears to be slow.

The sustained release double-layered tablet for oral administration containing itopride hydrochloride comprising the immediate-release layer and the sustained-release layer prepared according to the present invention can be prepared by dissolving the controlled release rate of the drug using a pharmaceutically acceptable release-controlling agent, The biological activity is equivalent, but when the effective therapeutic blood concentration is reached rapidly, it shows instantaneous improvement of gastrointestinal motility disorder as well as maintaining a constant concentration of active active ingredient and effective active metabolite in the plasma for a considerable time in the body.

In addition, the sustained-release bi-layer tablet of the present invention is characterized in that the dissolution characteristics are controlled more precisely than the conventional sustained-release tablet using a release modifier in which three kinds of hydroxypropylmethylcellulose having different viscosities are mixed, It is possible to elute the active ingredient uniformly for a long time while suppressing the initial excessive release in the body.

Fig. 1 shows the dissolution rates in the pH 1.2 eluant for the preparations prepared in each of the examples and the comparative examples.
Fig. 2 shows the dissolution rate in the pH 4.0 eluant for the preparations prepared in each of the examples and the comparative examples.
Figure 3 shows the dissolution rate in the pH 6.8 eluant for the preparations prepared in each of the Examples and Comparative Examples.
Figure 4 shows the dissolution rate in water for the formulations prepared in each of the Examples and Comparative Examples.

The preparation procedure of the two-layer structured Itopride hydrochloride sustained-release two-layer tablet according to the present invention is as follows.

The middle layer and the inner layer, including itopride hydrochloride, are mixed, combined and granulated to form granules. Then, the sustained-release bi-layer tablet is prepared by first preparing one of the middle layer and the middle layer, which is made of granules, and then filling the granules of the other layer with the granules.

Further, unlike the above-mentioned method, the sustained-release two-layer tablets of the present invention can also be prepared by separately preparing the slow-layer tablet and the inner layer tablet, and then tableting the tablets of each layer.

Hereinafter, one embodiment of the preparation method of the itopride hydrochloride sustained-release two-layer tablet according to the present invention will be described in detail.

Manufacturing method of the suspended layer granule

Hydroxypropylmethylcellulose having a viscosity of from 30 to 45% by weight of itopride hydrochloride, 30 to 40% by weight of microcrystalline cellulose and a viscosity of from 75,000 to 140,000 mPa.s as a pharmacologically active ingredient with respect to the total weight of the sustained-release layer, a viscosity of 11,250 to 21,000 mPa hydroxypropylmethylcellulose having a viscosity of 3,000 to 5,600 mPa.s, 10 to 20% by weight of a mixed release modifier of hydroxypropylmethylcellulose and 2 to 5% by weight of low-substituted hydroxypropylcellulose as a disintegrant %. 2 to 5% by weight of povidone dissolved in an appropriate amount of ethanol is added to the binding solution, which is then combined and granulated, and then dried and sieved to a LOD of 4% or less at a temperature of 60 DEG C in a fluidized bed dryer. Followed by mixing a suitable amount of gliding agents to form a sustained-release layer granule.

At this time, the release modifier mixed with the three types of hydroxypropylmethylcellulose having different viscosities, the hydroxypropylmethylcellulose having a viscosity of 75,000 to 140,000 mPa.s based on the total weight of the release modifier, %, Hydroxypropylmethylcellulose having a viscosity of 11,250 to 21,000 mPa.s, and hydroxypropylmethylcellulose having a viscosity of 3,000 to 5,600 mPa.s at a content ratio of 25 to 35% by weight do.

Meanwhile, the granule size of the sustained-release layer produced through the above process is 350 to 450 탆.

Manufacturing method of granule

15 to 40% by weight of itopride hydrochloride relative to the total weight of the immediate-release layer is mixed with 20 to 50% by weight of lactose, an appropriate amount of microcrystalline cellulose and 2 to 5% by weight of croscarmellose sodium and then povidone is dissolved in an appropriate amount of ethanol Weight% is added to the binding liquid, followed by coalescence and granulation, and dried and sieved to a LOD of 4% or less at a temperature of 60 DEG C in a fluidized bed dryer. Afterwards, an appropriate amount of lubricant flux is mixed to produce the immediate-layer granules.

Manufacturing method of sustained release double layer tablet

The above-prepared sustained-release granules and the pre-granulated granules are tableted at a rate of 30 to 40 rpm using a rotary tablet press with a pressure of preferably 3 to 8 kgf / cm 2, more preferably 4 to 6 kgf / cm 2.

The sustained-release bi-layer tablet according to the present invention can be prepared by first tableting the slow-layer granules with the tablet first, filling the granules with the granules, and then performing secondary tableting. However, It is not necessary that tableting of the immediate layer is performed, but tableting of the immediate layer is preferentially performed, and it is also possible to fill the granules of the sustained-release layer. Further, it is also possible to fill the inner layer and the middle layer sequentially or in reverse order, and to fix them once.

The total weight of the completed sustained-release bi-layer tablet is 400 to 500 mg. In order to improve the patient compliance with the medicament, the thickness of the tablets is preferably 4 to 9 mm, more preferably 5 to 7 mm.

The hardness of the sustained-release two-layer tablet according to the present invention is preferably 10 to 25 kg / cm 2, more preferably 15 to 20 kg / cm 2.

Hereinafter, preferred embodiments of the present invention will be described in detail. In the following Examples, specific components and specific factors for the practice of the present invention are described. However, the present invention is not limited by the following Examples. .

Examples 1 to 5 and Comparative Example 1

According to the ingredient contents in the following Table 1, the sustained release double-layer tablets of Examples 1 to 5 and Comparative Example 1 containing itopride hydrochloride were prepared.

Itopride hydrochloride bilayer formulation (unit: mg) division Classification ingredient Example 1 Example 2 Example 3 Example 4 Example 5 Comparative Example 1 book
room
layer available
ingredient Itopride hydrochloride 110 110 110 120 100 110 Release
Modulator Hypromellose 2208
(15000 mPa.s) 8.4 10.5 14.7 10.5 10.5 - Release
Modulator Hypromellose 2910
(4000 mPa.s) 13.6 13.6 11.5 13.6 13.6 22 Release
Modulator Hypromellose 2208
(100000 mPa.s) 23 20.9 18.8 20.9 20.9 23 Excipient Pending
cellulose 100 100 100 90 110 100 Binder Povidone K-30 10 10 10 10 10 10 Disintegration Low-substituted propyl cellulose 10 10 10 10 10 10 Lubricant Stearic acid
magnesium 5 5 5 5 5 5 Gross Weight 290 genus
room
layer available
ingredient Itopride hydrochloride 40 40 40 30 50 40 Excipient Lactose baggage 50 50 50 60 40 50 Excipient Pending
cellulose 40 40 40 40 40 40 Binder Povidone K-30 5 5 5 5 5 5 Disintegration Croscarmellose sodium 4 4 4 4 4 4 Lubricant Stearic acid
magnesium One One One One One One Gross weight 140 Coating layer Coating agent Opa Dry 0Y-C-7000A 15 Tablet weight 445

Detailed preparation steps of the respective examples and comparative examples based on the ingredient contents in Table 1 are as follows.

Immediate layer  Manufacture of granules

The povidone K-30 was gradually added to the ethanol solvent while stirring at an air pressure of 3 kg / cm < 2 > for 30 minutes to prepare a binding solution.

Ito-Pride hydrochloride and lactose hydrate, microcrystalline cellulose and croscarmellose sodium were mixed for 3 minutes in a speed mixer, and the resulting solution was added and mixed and coalesced three times for 3 minutes each time. Respectively.

The combined liquid was put into a rotary granulator and granulated for 20 minutes to form granules.

 The granules thus formed were dried in a fluid bed drier at 55 ° C for 40 minutes (LOD 2% or less), and the dried granules were formulated with a power mill for 20 minutes, then glidant was added and the mixture was stirred at 24 rpm in a drum mixer of 40 mesh stencil For 20 minutes to prepare the immediate-layer granules.

West floor  Manufacture of granules

The povidone K-30 was gradually added to the ethanol solvent while stirring at an air pressure of 3 kg / cm < 2 > for 30 minutes to prepare a binding solution.

Hydroxypropylmethylcellulose (HPMC 2208) having a viscosity of 100,000 mPa.s, hydroxypropylmethylcellulose (HPMC 2208) having a viscosity of 15,000 mPa.s, hydroxypropylmethylcellulose having a viscosity of 4,000 mPa.s Hydroxypropylmethylcellulose (HPMC 2910) and low-substituted hydroxypropylcellulose (L-HPC, 1/2) were mixed in a speed mixer for 3 minutes, and then the above- 3 times for 3 minutes to prepare a combined solution.

The mixed liquid was put into a rotary granulator and granulated for 20 minutes to form granules.

 The granules thus formed were dried in a fluidized bed drier at a temperature of 60 ° C (LOD 2% or less), and were sieved for 20 minutes. Thereafter, a lubricant made of hydroxypropylcellulose (L-HPC, 1/2) and a 40 mesh stencil And mixed in a drum mixer at a speed of 24 rpm for 20 minutes to prepare a sustained-release layer granule.

Preparation of sustained release double layer tablet

The granules of the late layer granules and the inner granules prepared in the above step were compressed at a speed of 34 rpm while applying a pressure of 4.5 kgf / cm 2 using a double rotary tablet press.

First, the granules of the middle layer were firstly tableted to prepare tablets. Secondary tablets were filled with the granules of the inner layer to prepare tablets.

The two-layered tablets were demineralized using a refining quench, and then coated with Opadry-OY-C-7000A (Colorcon Co.) for 120 minutes at a pump pressure of 3.0 bar and an air pressure of 2.5 bar using a 60- Coated with a coating agent, and then dried at 70 DEG C at a speed of 1 rpm for 10 minutes to prepare a sustained release bi-layer tablet of the present invention containing the active ingredient of itopride hydrochloride in one tablet.

In order to increase patient compliance, the thickness of the slow-release bilayer tablets was limited to 5 mm, the average hardness was 18.6 kg / cm 2, and the total weight of the completed two-layer tablets was 445 mg.

Invitro (In-vitro) elution test

The elution rate of itopride hydrochloride active ingredient in each of the formulations of the above Examples and Comparative Examples over time under the conditions of the Korean Pharmacopoeia dissolution test was measured to confirm the dissolution profile.

The test conditions used for the dissolution test are as follows.

Specimen: Itopride hydrochloride according to the examples and comparative examples Sustained-release two-layer tablets

Elution test solution: pH 1.2, pH 4.0, pH 6.8 and water

Amount of eluent: 900 ml, Test temperature: 37 ± 0.5 ° C

Test method: Korean Pharmacopoeia dissolution test No. 2 (paddle method), 50 rotations per minute

Sampling: 10 mL of the eluate is sampled every sampling time, filtered with a 0.45 μm filter to prepare the sample solution, and the eluate is sampled.

Analysis equipment: Ultraviolet spectrophotometer (UV-Vis), absorbance 273 nm

Test result

The results of the In-Vitro elution test are shown in Tables 2 to 5 below.

Elution rate at pH 1.2 division Dissolution rate (%) 15 minutes 30 minutes 60 minutes 90 minutes 120 minutes 180 minutes 300 minutes 360 minutes 480 minutes 600 minutes 720 minutes 1080 minutes 1440 minutes Example 1 22.3 28.9 36.5 42.1 46.4 54.3 64.5 69.5 77.3 83.6 88.7 96.5 100.2 Example 2 24.1 29.5 37.2 44.1 48.5 55.6 65.4 70.2 78.6 84.3 89.8 97.5 99.8 Example 3 21.5 27.6 35.8 41.5 46.2 54.1 62.5 68.2 76.2 82.3 85.3 97.8 99.4 Example 4 19.8 22.5 30.5 36.5 40.2 45.6 56.2 59.6 70.1 84.5 93.2 95.1 96.2 Example 5 20.1 21.5 31.9 35.5 39.8 44.3 57.1 59.2 71.5 85.6 94.2 95.9 95.2 Comparative Example 20.3 29.6 41.2 48.6 51.5 57.5 68.8 71.2 82.2 96.5 97.2 97.5 98.1

Elution rate at pH 4.0 division Dissolution rate (%) 15 minutes 30 minutes 60 minutes 90 minutes 120 minutes 180 minutes 300 minutes 360 minutes 480 minutes 600 minutes 720 minutes 1080 minutes 1440 minutes Example 1 21.9 30.7 38.4 44.2 49.2 57.2 68.5 72.4 80.8 87.1 92.4 98.2 99.5 Example 2 22.1 28.6 37.6 44.5 49.1 56.5 67.5 71.2 81.2 88.1 93.2 98.8 100.1 Example 3 21.4 29.2 38.2 43.5 48.2 55.8 66.4 70.3 82.3 88.9 91.5 97.6 99.6 Example 4 19.1 21.5 30.5 33.5 40.1 44.5 55.8 58.5 69.8 85.2 94.2 96.2 97.1 Example 5 19.5 22.2 29.8 34.5 39.8 45.2 56.1 60.2 68.8 84.2 95.2 96.7 96.8 Comparative Example 18.7 25.3 39.1 45.2 51.2 56.2 67.7 69.6 81.2 95.5 97.2 97.8 98.1

Elution rate at pH 6.8 division Dissolution rate (%) 15 minutes 30 minutes 60 minutes 90 minutes 120 minutes 180 minutes 300 minutes 360 minutes 480 minutes 600 minutes 720 minutes 1080 minutes 1440 minutes Example 1 24.6 31.5 38.4 43.3 47.3 54.2 63.2 67.2 74.1 78.7 83.1 94.9 99.5 Example 2 23.5 30.5 39.2 44.6 48.5 55.1 64.5 69.8 75.9 78.1 84.5 95.6 99.1 Example 3 24.1 31.2 36.5 45.2 47.6 56.2 65.3 68.8 76.8 79.6 85.2 96.1 98.6 Example 4 18.5 25.2 29.8 31.2 40.3 48.2 58.6 61.1 69.8 72.1 86.6 90.1 93.2 Example 5 17.5 23.3 28.8 33.5 41.1 47.9 56.8 62.1 69.1 72.5 78.8 91.1 92.5 Comparative Example 17.6 21.5 36.5 49.2 54.6 62.3 72.1 76.5 82.4 88.1 94.1 95.6 96.1

Elution rate in water division Dissolution rate (%) 15 minutes 30 minutes 60 minutes 90 minutes 120 minutes 180 minutes 300 minutes 360 minutes 480 minutes 600 minutes 720 minutes 1080 minutes 1440 minutes Example 1 20.6 28.9 37.2 44 49.2 56.9 67.8 73.2 81.3 86.8 91.3 96.7 99.5 Example 2 21.1 29.3 38.2 45.2 49.3 57.2 66.1 74.5 82.6 86.5 92.5 97.5 99.1 Example 3 22.1 30.1 39.1 46.2 50.1 58.1 68.2 75.6 80.8 88.4 94.5 95.5 100.1 Example 4 18.3 24.1 30.2 32.1 41.2 46.7 59.3 62.5 70.1 73.2 85.2 92.3 95.6 Example 5 16.2 22.5 28.8 30.3 42.3 48.3 57.5 64.5 71.6 71.5 80.1 91.5 94.9 Comparative Example 16.7 23.3 37.1 44.1 53.3 62.3 72.8 81.1 87.9 95.1 98.7 99.3 99.7

The dissolution profiles shown in the above table are shown in the graphs of FIGS. 1 to 4, and the dissolution profiles are analyzed. In the case of Examples 1 to 5, the elution was maintained constantly for 24 hours while exhibiting a highly preferable elution pattern. In the case of Comparative Example 1, the elution was relatively uniform, but the elution was rapid from 60 minutes to 12 hours, It was confirmed that most of the active ingredient was eluted

Relative activity factors and significance

The Applicant has found that when a sustained-release biodegradable tablet according to the present invention is orally administered to a patient, it is a meaningful criterion that can predict and discriminate whether or not a sustained effect can be exhibited through the stomach and intestinal environment sequentially, Relative activity factors were derived.

 [Equation 1]

In the case of the sustained-release two-layer formulation consisting of the immediate-release layer and the sustained-release layer, the effective ingredient of the rapidly eluting immediate-release layer after oral administration and the effective ingredient of the sustained-release sustained release layer are simultaneously absorbed in the body, The relative ratio of the effective ingredient dissolution rate of the active ingredient to the active ingredient dissolution rate of the sustained-release layer for the continuous effect is very important.

When the effective amount of the active ingredient in the immediate-release layer is excessively eluted at an early stage with respect to the effective ingredient in the immediate-release layer where the active ingredient elutes immediately, the blood concentration of the active ingredient may rapidly rise to cause side effects such as vomiting and dizziness. This is because the effect is rapidly lowered from the point of time when the effect of the eluted immediate-layer effective ingredient is stopped.

Therefore, the relative activity factor of the dissolution rate in the pH 1.2 environment in which the active ingredient of the immediate layer of the two-layer tablet is eluted and the dissolution rate in the pH 6.8 environment in which the active ingredient of the slow-release layer is gradually eluted gradually, And the effect of the two-layer tablet is a very desirable indicator that can be verified before oral administration.

The applicants calculated the relative activity of each of the examples and comparative examples according to the above formula (1), and the results are shown in Table 6 below.

Relative activity in pH 1.2 eluate to pH 6.8 division 15 minutes 3h 18h Example 1 0.907 1.002 1.017 Example 2 1.026 1.009 1.020 Example 3 0.892 0.963 1.018 Example 4 1.037 1.025 0.989 Example 5 1.149 0.925 1.053 Comparative Example 1 0.867 0.827 1.020

Review

In Examples 1 to 5, a release modifier mixed with three kinds of HPMCs having different viscosities was used. Due to the optimum content ratio, it was possible to control the elution more precisely, and the dissolution rate in Tables 2 to 5 and the dissolution rate As shown in the graph of FIG. 4, even after 30 minutes of elution of most of the immediate-release active ingredients, the effective drug elution rate was very favorable for 24 hours.

Further, as shown in Table 5, the relative activity in stomach and intestine was calculated from the dissolution rate at pH 1.2 and pH 6.8, and it was 0.89 to 1.15 after 15 minutes of elution, 0.92 to 1.03 after 3 hours, Is 0.99 to 1.06, the optimum elution activity is shown as in Examples 1 to 5 above.

In the case of the sustained-release bi-layer tablet according to the present invention, when the relative activity is out of the above range, elution is delayed or the duration is shortened as shown in FIGS.

Claims (8)

As a once-daily oral administration sustained-release or controlled-release double-layer tablet containing itopride hydrochloride as an active ingredient,
An active ingredient, a filler, a binder, a disintegrant,
An active ingredient, a filler, a binder, a disintegrating agent and a release modifier,
Wherein the release modifier comprises:
Hydroxypropylmethylcellulose having a viscosity of 75,000 to 140,000 mPa.s,
Hydroxypropylmethylcellulose having a viscosity of 11,250 to 21,000 mPa.s and
And hydroxypropylmethylcellulose having a viscosity of 3,000 to 5,600 mPa.s are mixed and used,
Relative to the total weight of the release modifier
The hydroxypropylmethylcellulose having a viscosity of 75,000 to 140,000 mPa.s is contained in an amount of 40 to 55% by weight,
15 to 35% by weight of hydroxypropylmethylcellulose having a viscosity of 11,250 to 21,000 mPa.s,
Wherein the hydroxypropylmethylcellulose having a viscosity of 3,000 to 5,600 mPa.s comprises 25 to 35% by weight of the hydroxypropylmethylcellulose.
The method according to claim 1,
Wherein the immediate-release layer contains 20 to 60 mg of active ingredient, and the sustained-release layer contains 90 to 130 mg of active ingredient.
The method according to claim 1,
The sustained release layer comprises, based on the total sustained release layer total weight,
Characterized in that it comprises 30 to 45% by weight of itopride hydrochloride, 10 to 20% by weight of the release modifier, 2 to 5% by weight of low-substituted hydroxypropyl cellulose and 2 to 5% by weight of povidone K-30 Orally administered sustained-release double-layer tablet containing itopride hydrochloride.
The method according to claim 1,
Wherein the total weight of the isopride hydrochloride-containing oral administration sustained-release two-layer tablet is 400 to 500 mg.
The method according to claim 1,
And the thickness of the sustained-release sustained-release two-layer tablet containing itopride hydrochloride is 4 to 9 mm. The sustained-release sustained release double-layer tablet containing itopride hydrochloride.
A process for preparing itopride hydrochloride-containing sustained release double-layered tablet, which is orally administered once a day according to claim 1,
Mixing itopride hydrochloride granules, release modifiers, fillers, binders and disintegrants to produce sustained-release granules;
Mixing the itopride hydrochloride granule, the filler, the binder and the disintegrant to produce a granule of the immediate layer;
Wherein the sustained-release sustained-release double-layer tablet containing itopride hydrochloride is prepared by compressing the granules of the immediate-release layer and the granules of the sustained-release layer with a force of 3.0 to 8.0 kgf per unit area of 1 cm 2. Gt;
The method according to claim 6,
Wherein the sustained-release layer granules have a diameter of 350 to 450 mu m.
The method according to claim 6,
Wherein the single tablet has a hardness of 10 to 25 kg / cm < 2 >.

Images